IMMUNOGLOBULIN BINDING PROTEINS DERIVED FROM L PROTEIN AND THEIR USES

Abstract: Synthetic molecules having one or more binding regions with binding affinity for Kappa light chains of immunoglobulins, processes for their production and recombinant DNA coding therefor.

Description: Immunoglobulin binding proteins derived from L protein and their uses This invention relates to novel immunoglobulin binding proteins, processes for their production and reco binant DNA molecules coding therefor. More specifically the present invention relates to synthetic proteins containing repeated sequences derived from selected binding regions of Protein L and to recombinant DNA molecules coding therefor. A multitude of Gram-positive bacteria species have been isolated that express surface proteins with affinities for mammalian immunoglobulins through interaction with their heavy chains. The best known of these immunoglobulin binding proteins are type 1 Staphylococcus Protein A and type 2 Streptococcus Protein G which have been shown to interact principally through the C2-C3 interface on the Fc region of human immunoglobulins. In addition, both have also been shown to interact weakly to the Fab region, but again through the immunoglobulin heavy chain. Recently, a novel protein from Peptococcus magπus . Protein L, has been reported that was found to bind to human, rabbit, porcine, mouse and rat immunoglobulins uniquely through interaction with their light chains. In humans this interaction has been shown to occur exclusively to the kappa chains. Since both kappa and lambda light chains are shared between different classes. Protein L binds strongly to all human classes, in particular to the multi-subunited IgM, and similarly is expected to bind to all classes in species that show Protein L light chain binding. Both peptococcus and peptostreptococcus have been reported to produce Protein L, which binds to the Kappa light chain of human immunoglobulins. It has been proposed that Protein L is a virulence factor; non-virulent peptococci and peptostreptococci appear to neither express Protein L nor have the structural gene for it (Kastern et al 1990) . Protein L is of particular interest since it has been reported to bind to the Kappa light chain which is present in all classes and sub classes of immunoglobulins. As such it should prove to be a useful diagnostic reagent for use in ELISA and RIA techniques. EP-A-0255 ^ 7 describes the purification and attempted characterisation of Protein L by standard protein purification techniques. Subsequently, the authors of EP-A-0255 -^97 have published a number of scientific papers describing further investigations into the nature and structure of Protein L, but to date, attempts fully to characterize the protein have failed. Thus recently, in a paper entitled "Protein L a Bacterial Immunoglobulin-Binding Protein and Possible Virulence Determinant" by W. Kastern et al (Infection and Immunity, May 1990, pp. 1217-1222) there are described unsuccessful attempts to isolate the gene coding for Protein L by determining N-terminal amino acid sequences of tryptic fragments of Protein L and using the derived sequence information to construct probes for isolating the gene. Although Protein L is useful for its immunoglobulin binding properties it is desirable to identify whether particular regions of Protein L confer immunoglobulin binding so that these regions may be used as the basis for construction of synthetic and improved immunoglobulin binding molecules. Due to lack of sequence information, it has hitherto not been possible to identify the Protein L sequences associated with complex formation with immunoglobulin Kappa light chains. Hitherto, the problem of isolating and characterising the gene for Protein L has defined solution thereby preventing significant improvement in production of Protein L and preventing development of synthetic molecules derived from Protein L. This invention is based on a cDNA sequence comprising a cDNA insert coding for Protein L in its entirety which has now been isolated, thus enabling the above problems to be solved. This cDNA sequence, and the amino acid sequence corresponding to the longest open reading frame thereof, are depicted in Figure 1. The beginning of the signal sequence is marked as "SS" and the beginning of the mature protein is marked as "M" . The longest open reading frame of the sequence depicted in Figure 1 extends from TTG (103) to AAA(3183) and the depicted DNA comprises a coding region extending from nucleotide 208 to nucleotide 3183 which codes for immature Protein L. The specific binding properties of Protein L, including its ability to bind immunoglobulin Kappa light chains, are believed to be attributable to the presence of sequences which have a recognisably repeated character within the amino acid sequence of the molecule. By the term "recognisably repeated character" as used herein is meant that the amino acid sequence comprises at least two sequences, each of from 20 to ~~ amino acids in length (or from 40 to 90 amino acids in length in the case of the D repeats), which have an at least 75%, preferably at least 90% and most preferably at least 95% homology with one another. The polypeptide sequence depicted in Figure 1 includes various sets of repeated sequences at least two of which are considered to be responsible for immunoglobulin Kappa light chain binding. These sets of repeated sequences are labelled at their N-terminal ends as follows: (1) Al, A2 and A3; (2) Bl and B2; (3) Cl, C2, C3, and C4; (4) Zl. 12 , Z3 and Z-4; (5) Dl, D2, D3 and D<4 ; Each of the repeated sequences (1) - (4) has a length of between 25 and 4 amino acids. The ability to bind Kappa light chains is considered to be associated with one or more of the repeated sequences A r B, C and Z (sequences (1) - (4) above). It is thus a feature of a first aspect of the invention to provide synthetic immunoglobuiin binding molecules comprising a plurality of recognisably repeated binding domains selected from the sequences which are labelled at their N-terminal ends in Figure 1 as Al, A2 and A3; Bl, and B2; Cl, C2, C3, and C4; and Zl, Z2, Z3 and Z4. The synthetic immunoglobulin binding molecules preferably comprise from 2 to 15 of said domains. The selected domain or domains may be identical to the sequences which are labelled at their N-terminal ends in Figure 1 as Al, A2 and A3; Bl, and B2; Cl τ C2, C3, and C4; Zl, Z2, Z3 and Z4, or they may vary from said sequences, provided that they have an at least 75%. preferably at least 30% and most preferably at least 95» homology therewith. The sequences labelled at their N-terminal ends as Dl, D2, D3 and D4 are believed to be resposible for albumin binding and the synthetic binding molecules provided according to the invention may include sequences selected from sequences Dl, D2, D3 and D4 or related squences which vary from said sequences, provided that they have an at least 757^. preferably at least 90% and most preferably at least 95 homology therewith. In an embodiment of the invention hereinafter described a synthetic immunoglobulin binding molecule is provided in which domains Cl and Zl, and/or C2 and Z2 and/or C3 and Z3 and/or C and Z4 are present as binding region or regions. Region C1Z1 begins at the first amino acid of Cl and ends at the last amino acid of Zl, etc. - According to a further embodiment of the invention a synthetic immunoglobulin binding molecule comprises one or more immunoglobulin binding regions selected separately from: (1) region C1Z1 of protein L, (2) region C2Z2 of protein L, (3) region C3Z3 of protein L, (4) region C4Z4 of protein L, and (5) a polypeptide sequence having at least 75% homology with one of the regions of (1), (2), (3) or (4) and substantially retaining the immunoglobulin binding activity of that region. It is preferred that the synthetic molecule is substantially free of one or both of (1) protein L albumin binding activity and (2) protein L cell wall binding activity. The sequence data shown in the figures indicate that regions C1Z1, C2Z2, C3Z3 and C4Z4 of protein L shown are respectively 71, 71, 7 and 75 amino acid residues in length. References in the invention to these regions are intended to encompass variants of these precise sequences. One such variant retains substantially the immunoglobulin binding activity of the precise sequence and has up to ten preferably up to 5 and very preferably no more than 2 amino acids substituted, added or deleted. Another variant exhibits a degree of homology with one of the C1Z1, C2Z2, C3Z3 and C4Z4 sequences of 75% or more, preferably 90% or more while retaining substantially the immunoglobulin binding activity of the precise sequence. The binding regions of the synthetic molecule are ligated directly to one another in one embodiment of the invention. In another embodiment binding regions are separated from each other by linker polypeptides, the nature of each linker being such as not to interfere with the binding activity of the binding domain. Linker polypeptides if present are preferably of up to 10 amino acids in length and most preferably up to amino acids in length. Although the invention includes synthetic molecules having a large number of binding regions It is convenient for the synthetic molecule to have from 1 to 4 such regions. In a preferred embodiment of the invention the synthetic molecule has four such regions. The selection of a particular C Z or C Z -derived variant sequence for each of the four regions is optional. Thus the synthetic molecules of the invention cover a large number of possible combinations of C Z and C Z - derived variant n n n n sequences. In a particular embodiment of the invention a synthetic molecule has four binding regions one each selected from C1Z1 or a variant thereof, C2Z2 or a variant thereof, C3Z3 or a variant thereof and C4Z4 or a variant thereof. An example of such an embodiment is shown in Fig 2 which binds to immunoglobulin as native Protein L but does not bind to albumin or cell wall as native protein L. The synthetic molecules of the invention can conveniently be used to form products for use in protein analysis, purification procedures and other biochemical processes according to methods well known in the art. The synthetic immunoglobulin binding molecules can, for example, be ligated to a "reporter" molecule, such as an enzyme so as to be suitable for enzyme linked immunoabsorbent assay (ELISA) . In another example to "reporter" molecule is suitable for use in a chemiluminescent assay. The synthetic molecules of the Invention can additionally be ligated to a molecule suitable for attachment to a solid support, such as a cysteine residue for attachment to a further cysteine residue on a solid matrix, or his idine for attachment to zinc on a support, or a mussel derived adhesive protein for attachment to a wide variety of surfaces including glass. Thus the invention provides novel synthetic immunoglobulin binding molecules that are useful in a wide range of biochemical applications. The synthetic molecules are of particular advantage if they are free from regions Dl, D2, D3 and D4 and as a result they do not exhibit the albumin binding and cell wall binding of native protein L, The synthetic molecules of the invention can conveniently be used to form products for use in protein analysis, purification procedures and other biochemical processes according to methods well known in the art. According to a second aspect of the invention there is provided a recombinant DNA molecule containing an insert coding for a synthetic molecule according to any embodiment of the first aspect of the invention. A nucleotide sequence of an embodiment of the second aspect of the invention is shown in Fig. 2. It is straightforward for a man skilled in the art, once in possession of the DNA sequence coding for a desired polypeptide, to construct a vector capable of transforming a host cell so as to express that polypeptide. Thus, according to a third aspect of the invention there is provided a process for producing a synthetic molecule of the first aspect of the invention comprising the steps of (a) transforming a host cell with an expression vector capable of transforming the host cell so as to express the synthetic molecule, (b) culturing the transformed host cell, and (c) isolating the synthetic molecule. One such expression vector is plasmid pPPL2 described below and which has been deposited at NCIMB, Aberdeen, Scotland, UK under accession No. 4053*** on 22 December 1992. There now follows a description of exemplary embodiments of the invention in which:- Fig.l shows the nucleotide sequence of the gene coding for Protein L together with the amino acids coded for; Fig. 2 shows the nucleotide sequence and the amino acid sequence coded thereby of an embodiment of the invention; and Fig. 3 shows a schematic representation of two different Protein L isolates and deletion clones constructed to determine the function of the separate binding domains. Fig. 3 shows l.(a) Domain structure as determined by Kastern et at. . Infect. Immunol., 8, 1992, and l.(b) domain structure as determined by Murphy et al. , Eur J. Biochem, 168, 1992. Shaded areas between the two figures represent areas of strong homology. To determine the domains responsible for the immunoglobulin-kappa binding reported for both molecules, and the albumin-binding reported for 1. (b) , the deletion clones (constructed from the gene expressing l.(b)) are shown in 2. (a,b,c) . Example 1 Materials X-Omat S X-ray film was from Kodak. DNA ligase, restriction endonucleases and other DNA-modlfying enzymes were from Boehringer. Agarose, acrylamide, bis-acrylamide and phenol were from Bethesda Research Laboratories. Chromatography media was from Pharmacia LKB (Uppsala, Sweden) . All immunoglobulins and serum albumin were from Sigma. All other reagents were from Sigma of BDH. Nunc 96 well microtitre plates were purchased from Gibco BRL Ltd. Media and Cutlure conditions E. coli TGI was cultured in 2xYT both (2% (w/v) tryptone/1% (w/v) yeast extract/1% (w/v) NaCl) overnight at 37°C. Media were solidified with 2% (w/v) Bacto-agar (Difco) . Ampicillin (50μg/ml) were used where necessary for the selection and growth of transformants. Functional β-galactosidase was detected by addition of chlorindolyl-β-D-galactoside to a final concentration of 600 μg/ml and, where necessary, isopropyl-β-D-thiogalactopyranoside to a final concentration of 200 μg/ml. Isolation of DNA Plasmid DNA was purified from E. co li by Brij lysis (Clewell and Helsinki, PNAS, USA, 1969) and CsCl/ ethidium bromide density-gradient centrifugation (Radloff et al . , PNAS, USA 1967). Genetic Manipulation Procedures DNA-modifying enzymes were used in the buffer and under the conditions recommended by the supplier (Boehringer) . Transformation of E. co li was essentially as described previously (Cohen et al . , PNAS, USA 1972) . Electrophoresis of DNA fragments was performed on vertical 1% (w/v)-agarose slab gels in Tris-acetate buffer (40 mM-Tris/ /20mM-sodium acetate/ 2mM-EDTA, adjusted to pH 7.9 with acetic acid). DNA fragment sizes were estimated by comparison with fragments of lambda phage DNA previously digesed with the restriction endonuclease Hind III. DNA fragments were purified by electro-elution essentially as described previously (McDonnell et al . , J. Mol. Biol., 100, 1977)- Constriction of deletion clones A schematic representation of the deletion clones constructed are shown in Fig. 3- pPPLl was constructed by amplifying the DNA fragment indicated in Fig. 3 (2a) isolating the A, B, C and Z repeats. To facilitate expression, an iVtfel site (CAT ATG) was incorporated into the sense primer (5*-TTA AAT CAT ATG TCA GAA ACA-3') and to prevent -read through, a stop condon was incorporated into the anti-sense primer (5'-CC TGG TTG TTA TTT TCC AGC AAA T-3' ) . This fragment was cloned into the TA cloning vector (Amersham) , and subsequently excised on a iVdel-partial Hind III (cleaving at the Hind III site present in the TA cloning vectors polylinker) fragment, and re-cloned inframe into the iVdel-Hind III cleaved expression vector pMTL1013 (Brehm et al . , Appl. Microbiol. Bitechnol., 36, 1991). pPPL2, expressing only the C and Z repeats, was derived from pPPLl by excision of the gene fragment shown in Fig. 3 (2b) through an Eco RV-Spel (site carried over from the TA cloning vector polylinker) digest, and re-cloned inframe into Smal-Xbal cleaved pMTL1013. pPPL3 (Fig. 3 (2c)), expressing the D and E repeats, was obtained through a Pstl (present upstream of the PPL open reading frame)-partial Hind III digest and cloned inframe into Hind III-Pstl cleaved pMTL23 (Chambers et al. , Gene, 68, 1988) . PCR PCR was achieved by synthesising oligonucleotides (synthesised by solid phase synthesis using an Appied Biosysterns Model 38OA DNA synthesiser employing phosphoamidites) either side of the target site on the PPL gene and DNA fragments generated by the polymerase chain reaction using the method and reagents supplied in the PCR-Perking Elmer TM Cetus GeneAmp kit. Sonication of cells A cell suspension was transferred to a MSE sonication tube and subjected to ultra sonication (3x30 sec bursts at lδMHz with 30 sec intervals, at 4 ° C using an MSE Soniprep 150 Sonicator) . Affinity Chromatography on IgG-Sepharose 4B The sonication procedure was used to disrupt bacterial cells for small scale purification of immunoglobulin-binding proteins by affintity chromatography on IgG-sepharose FF. Cultures of 300ml were grown overnight then centriguted (15000g for 10 min at 4°C) and resuspended in 3ml of 100 mM Tris-HCl, pH 7.5, 250 mM NaCl. The suspension was sonicated, centrifuged (30000g 10 min at 4°C) and the supernatant fluid passed through a 1ml column (1.6cm x 0.90cm i.d.) of IgG-sepharose FF equilibrated and washed with 5ml of 100 mM Tris-HCl, pH 7.5, 250mM NaCl. The protein was eluted with lOOmM gylcine-HCl, pH 2.0, and the pH raised to 7.5 using 1M Tris, pH 8.0. PAGE Samples were solubilised under reducing condition and electrophoresis on SDS-polyacrylamide slab gels. Acrylamide (12.5% w/v) slab gels were run in an LKB vertical electrophoresis unit using the method of Laemmli (Laemmli, Nature, 227, 1970). Proteins were stained with Commassie Brilliant Blue R-250, and protein bands were scanned with a Chromoscan-3 laser optical densitometre (Joyce-Loebl, Gateshead, Tyne and Wear, U.K.), to estimate the apparent M . Elisa Detecton assay Immunoglobulin-binding proteins were detected using an Elisa procedure modified from that previously described (Warenes et al . , J. Immunol. Methods., 93, 1987) . Detection of immunoglobulin-binding An aliquot of mouse IgG (100 μl) at 2.5μg/ml in 50mM sodium carbonate/bicarbonate buffer, pH9.6 was added to each well of a Maxisorp plate and the plate left overnight at 4 ° C. Following three washes with PBST-Phosphate buffered saline containing 0.05% (v/v) Tween 20, a lOOμl aliquot of the suspension of recombinant bacteria was transferred to the Maxisorp plate from overnight cultures. The immunoassay plate was then left at room temperature for an hour. After washing with PBST, lOOμl of human IgG at lμg/ml in PBST was added to each well and the plate left at room temperature for another hour. After a further wash, * 100μl of goat anti-human IgG (Fc specific) horseradish peroxidase conjugate (diluted 1:2000 in PBST was added to each well and the plate left at room temperature for a further hour. After further washing, lOOμl of reagent (60μg/ml 3,3', 5,5'-Tetramethylbenzine dihydrochloride, 0.003% (v/ ) hydrogen peroxide in 0.1M sodium acetate buffer, pH6.0) was added to each well and the reaction allowed to proceed for lOmin at room temperature. After this the reaction was stoped by the addition of 50μl 11% (v/v) sulphuric acid to each well. The absorbance of the wells were then read at 450nm against a reagent blank to measure the levels of immunoglobulin-binding proteins. Detection of albumin-binding To detect albumin-binding, the above procedure was followed except different affinity reagents were used in each step of the sandwich. The first step bound the protein sample under investigation, which has been prepared by recovering the cell supernatant following sonication, to the Maxisorp plate. Albumin-binding was then detected by incubating the plate with human serum albumin (HSA, lμg/ml) followed by goat-anti HSA IgG-horseradish peroxidase conjugated (1:2000 dilution) , and then developed as above. The following results were obtained. pPPLl and pPPL2 (Fig. 2 (2a,b)) were shown by Elisa to bind to IgG, lacking any albumin binding. pPPL3 (Fig 2 (2c)) In contrast bound HSA, but not IgG. This shows that Kappa binding was through the C and Z repeats and that the albumin-binding was at a separate site located in the D- or E-repeats. A purified solution of a synthetic immunoglobulin building molecule according to the invention can be obtained using the following method. Host cells transformed with pPPL2 are grown, eg in a 4001 to 40001 fermenter. The cell culture is then removed from the fermenter and spun down to obtain a cell paste, the supernatant culture medium being discarded. The cell paste is washed in potassium phosphate buffer (pH 6.5) and lysosyme is added to lyse the cells over a suitable period of for example 30 to 60 minutes. The lysed cells are next heated to 70 ° C for 15 minutes and then centrifuged at 13000 rpm for 2 hours, leaving a supernatant of soluble, crude protein which is removed from the centrifuged pellet and can be stored at -20°C. To obtain a sample of the synthetic molecule the crude protein, either thawed from store or direct from centrifuging is eluted through a Q-Sepharose column previously equilibrated with potassium phosphate buffer (pH 6.5). Before being added to the column the crude protein solution is diluted so as to be at the same ionic strength as the buffer. The column is washed with buffer until no more protein is washed off, then washed with 50 NaCl solution to remove proteins binding weakly to the column. The strength of NaCl solution used to elute the column is then increased in steps and the protein fractions obtained kept separate. The synthetic protein molecule of the invention is obtained from elution with NaCl between 270-290 mM. The synthetic protein molecules of the invention, exemplified by that obtained as described above, find advantageous use in bio-assays and other biochemical applications due to their ability to bind to Kappa light chains of immunoglobulins. They are of use for example in ELISA, RIA, diagnosis, antibody purification. Fig. 1 of GB 9209804.5 from which priority is claimed is reproduced as Fig. 1 of this application but with different nomenclature as set out below: GB 90980 . This Application Al, A2, A3 Al, A2, A3 Bl, B2 Bl, B2 Cl, C2, C3, C4 Cl, C2, C3, C4 Dl, D2, D3, D4 Zl, Z2, Z3, Z4 El, Fl *D1 E2, F2 *D2 E3, F3 *D3 E4, F4 *D4 This application uses the same nomenclature as the second priority application, GB 9226928.1. *The sequence now marked as Dl consists of the sequence originally marked El together with the sequence orginally marked Fl, etc.

Claims: CLAIMS 1. A synthetic immunoglobulin binding molecule comprising a plurality of recognisably repeated binding domains selected from the sequences . which are labelled at their N-terminal ends in Figure 1 as Al, A2 and A3; Bl, and B2; Cl, C2, C3, and C4; and Zl, Z2, Z3 and Z4: 2. A synthetic molecule according to Claim 1 comprising from 2 to 15 of said domains. 3. A synthetic immunoglobulin binding molecule according to Claim 1 or Claim 2 wherein the selected domain or domains are identical to the sequences which are labelled at their N-terminal ends in Figure 1 as Al, A2 and A3; Bl, and B2; Cl, C2, C3, and C4; and Zl, Z2, Z3 and Z4, or vary from said sequences, provided that they have an at least 75%. preferably at least 90% and most preferably at least 95% homology therewith. 4. A synthetic molecule according to any of Claims 1 to 3 wherein said domains are from 20 to amino acids in length. 5. A synthetic molecule according to any of Claims 1 to 4 additionally including domains selected from sequences Dl, D2, D3 and D4 or related squences which vary from said sequences, provided that they have an at least 75%. preferably at least 90 and most preferably at least 95% homology therewith. 6. A synthetic molecule according to any of Claims 1 to 5 wherein the binding domains are selected from sequences Cl, C2, C3, C4, Zl, Z2, Z3 and Z4. 7. A synthetic molecule according to Claim 6 comprising a binding region consisting of Cl linked at its C-terminus to Zl. 8. A synthetic molecule according to Claim 6 or Claim 7 comprising a binding region consisting of C2 linked at its C-terminus to Z2. 9. A synthetic molecule according to any of Claims 6, 7 or 8 comprising a binding region consisting of C3 linked at its C-terminus to Z3. 10. A synthetic molecule according to any of Claims 6 to 9 comprising a bindin region consisting of C4 linked at its C-terminus to Z -^ 11. A synthetic molecule according to any preceding claim in which all of domains Dl, D2, D3 and D4 are absent. 12. A synthetic molecule according to any preceding claim comprising the amino acid sequence of Fig. 2. 13- A nucleotide sequence coding for a synthetic molecule according to any preceding claim. 14. A recombinant DNA molecule comprising a sequence according to Claim 13. 15. A method of producing a synthetic immunoglobulin binding molecule comprising the steps of (1) forming an expression vector capable of transforming a host cell so as to express a polypeptide coded for by a DNA coding sequence according to Claim 14 (2) transforming a host cell with the vector (3) culturing the host cell, and (4) isolating substantially pure product from the host cell. 16. A method according to Claim 15 in which the vector is pPPL2.

Inventors: ATKINSON ANTHONY, DUGGLEBY CLIVE JAMES, MURPHY JONATHAN PAUL, TROWERN ANGUS ROBERT, ATKINSON, ANTHONY, DUGGLEBY, CLIVE, JAMES, MURPHY, JONATHAN, PAUL, TROWERN, ANGUS, ROBERT
Applicants: ATKINSON ANTHONY, DUGGLEBY CLIVE JAMES, HEALTH LAB SERVICE BOARD, MURPHY JONATHAN PAUL, TROWERN ANGUS ROBERT, PUBLIC HEALTH LABORATORY SERVICE BOARD
Application year: 1993
Main classification: C12N15
IPC codes: C07K1, C07K14, C12N15, C12P21